Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Astrocytoma

• Re-Administration of C134 in Patients With Recurrent GBM (C134-HSV-1)
• Study of Olutasidenib and Temozolomide in HGG
• T Cells and Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma
• Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
• Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
• Study of Ribociclib and Everolimus in HGG and DIPG
• A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
• A Study of Temodar With PCI-24781 for Patients With Recurrent Glioma
• Venous Thromboembolism Prevention in Outpatients With Glioma
• Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients With Recurrent High-Grade Glioma
• Evaluation of ex Vivo Drug Combination Optimization Platform in Recurrent High Grade Astrocytic Glioma
• Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Astrocytoma
• Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive Enhancing IDH-1 Mutant Astrocytomas
• A Phase 2 Trial of All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma
• PARP Inhibition for Gliomas (PI-4G or π4g)
• Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma
• A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine Glioma and H3 K27M-Mutant High-Grade Glioma
• A Phase I/II Study of Pembrolizumab and M032 (NSC 733972)
• Study of Icapamespib (PU-AD) in Patients With Recurrent Malignant Glioma
• Tadalafil to Overcome Immunosuppression During Chemoradiotherapy for IDH-wildtype Grade III-IV Astrocytoma
• Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
• Convection-enhanced Delivery of OS2966 for Patients With High-grade Glioma Undergoing a Surgical Resection
• Surgical Nivolumab And Ipilimumab For Recurrent GBM
• A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma
• Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
• HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma
• Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
• A Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511
• INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas
• WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases
• A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
• Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma
• Evaluate the Safety and Effectiveness of Intranasal Administration of Temozolomide in Patients With Glioblastoma
• A Phase II Study of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma
• CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma
• Pediatric Long-Term Follow-up and Rollover Study
• Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG
• Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas
• Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma
• Fimepinostat in Treating Brain Tumors in Children and Young Adults
• Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases
• Hyperfractionated RT With BCNU Versus Conventional RT With BCNU for Supratentorial Malignant Glioma
• Investigation of Oral OKN-007 in Recurrent High-grade Glioma Participants
• Efficacy of Two Temozolomide Regimens in Adjuvant Treatment of Patients With Brain High Grade Glioma
• HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
• HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
• Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations
• CB-839 With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma
• SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors
• A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)
• Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 2
• International Cooperative Phase III Trial of the HIT-HGG Study Group (HIT-HGG-2013)
• Study of TG02 in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma
• A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer
• Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma
• A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2
• TVB- 2640 in Combination With Bevacizumab in Patients With First Relapse of High Grade Astrocytoma
• Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma
• Laser Interstitial Thermal Therapy and Lomustine in Treating Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma
• BPM31510 in Treating Patients With Recurrent High-Grade Glioma Previously Treated With Bevacizumab
• Autologous Stem Cell Collection and Reinfusion in Newly Diagnosed High Grade Gliomas
• Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases
• Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma
• Pilot Study of Cabozantinib for Recurrent or Progressive Central Nervous System Tumors in Children
• Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma
• Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
• Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients
• A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent Glioblastoma Multiforme (GBM)
• First in Patient Study for PF-06840003 in Malignant Gliomas
• Prolonged Exposure to Doxorubicin in Patients With Glioblastoma Multiforme and Diffuse Intrinsic Pontine Glioma
• Expanded Access to ANG1005 for Individual Patients
• Phase II Pediatric Study With Dabrafenib in Combination With Trametinib in Patients With HGG and LGG
• Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001
• Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors
• A Study on β-elemene as Maintain Treatment for Newly Diagnosed Malignant Gliomas
• A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
• Nivolumab With DC Vaccines for Recurrent Brain Tumors
• Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma
• A Safety Study of Fingolimod With Radiation and Temozolomide in Newly Diagnosed High Grade Glioma
• Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme
• The Addition of Chloroquine to Chemoradiation for Glioblastoma,
• The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
• Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors
• DC Migration Study for Newly-Diagnosed GBM
• Pegylated Interferon ALFA-2b in Children With Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
• Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors
• Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas
• A Prospective Cohort to Study the Effect of Temozolomide on IDH Mutational Low Grade Gliomas
• Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas
• Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas
• 18F-FDOPA PET/CT or PET/MRI in Measuring Tumors in Patients With Newly-Diagnosed or Recurrent Gliomas
• Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma
• Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma
• Genetically Modified Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas
• Oncolytic HSV-1716 in Treating Younger Patients With Refractory or Recurrent High Grade Glioma That Can Be Removed By Surgery
• Everolimus With and Without Temozolomide in Adult Low Grade Glioma
• Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas
• Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors
• 3T MRI Biomarkers of Glioma Treatment Response
• Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor
• p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors
• Phase I Study of Safety and Immunogenicity of ADU-623
• Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas
• Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22
• Valproic Acid in Childhood Progressive Brain Tumors
• A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas
• Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors
• Dose Evaluation Safety STudy IN Individuals With Astrocytoma Taking PolyMVA
• Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma
• A Phase III Trial on Adjuvant Temozolomide With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas
• Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas
• Phase-1 Study of Folinic Acid to Modulate MGMT Gene in Glioblastoma
• Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma
• Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma
• Efficacy of Tranexamic Acid in Brain Tumor Resections
• Efficacy of Post-radiation Adjuvant Temozolomide Chemotherapy in Residue Low-grade Glioma
• Carboplatin in Treating Patients With Recurrent High-Grade Gliomas
• Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Recurrent Malignant Glioma
• Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
• Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
• Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas
• Phase I Study of Orally Administered Aminolevulinic Acid for Resection of Malignant Astrocytomas
• Phase III Trial of Primary Radio- or Chemotherapy in Malignant Astrocytoma of the Elderly
• Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas
• AMG 595 First-in-Human in Recurrent Gliomas
• Study of a Retroviral Replicating Vector Combined With a Prodrug to Treat Patients Undergoing Surgery for a Recurrent Malignant Brain Tumor
• Low Dose Radiation Therapy for Glioblastoma Multiforme
• Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma
• Safety and Efficacy Study of TH-302 CNS Penetration in Recurrent High Grade Astrocytoma Following Bevacizumab
• Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma
• BIBF 1120 for Recurrent High-Grade Gliomas
• High-Dose Vorinostat and Fractionated Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Glioma
• A Study of Aminolevulinic Acid Used to Enhance Visualization and Surgical Removal of Brain Tumors
• Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma
• Sorafenib in Children and Young Adults With Recurrent or Progressive Low-Grade Astrocytomas
• Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors
• Access Protocol for MAB-425 Radiolabeled With I-125 for High Grade Gliomas
• AZD8055 for Adults With Recurrent Gliomas
• Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
• Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma
• Exploratory Study of XL765 (SAR245409) or XL147 (SAR245408) in Subjects With Recurrent Glioblastoma Who Are Candidates for Surgical Resection
• Super-Selective Intraarterial Cerebral Infusion of Cetuximab (Erbitux) for Treatment of Relapsed/Refractory GBM and AA
• Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma
• Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases
• A Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma
• Lenalidomide and Radiation Therapy in High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas
• Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma
• RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma
• Super-Selective Intraarterial Cerebral Infusion Of Temozolomide (Temodar) For Treatment Of Newly Diagnosed GBM And AA
• A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas
• Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor
• Fluorine F 18 Fluorodopa-Labeled PET Scan in Planning Surgery and Radiation Therapy in Treating Patients With Newly Diagnosed High- or Low-Grade Malignant Glioma
• A Study of a Retroviral Replicating Vector Combined With a Prodrug Administered to Patients With Recurrent Malignant Glioma
• Pioglitazone Hydrochloride in Preventing Radiation-Induced Cognitive Dysfunction in Treating Patients With Brain Tumors
• Aminolevulinic Acid During Surgery in Treating Patients With Malignant Brain Tumors
• Cellular Immunotherapy Study for Brain Cancer
• Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors
• A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB
• RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma
• Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma
• Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma
• Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
• Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
• Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors
• Study of Multiple Doses and Regimens of XL184 (Cabozantinib) in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse
• Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma
• A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma
• A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas
• Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
• A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors
• Super-Selective Intraarterial Intracranial Infusion of Avastin (Bevacizumab)
• ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors
• Study of 18F-FEC for Positron Emission Tomography-Computed Tomography (PET-CT) Imaging of GBM
• A Study to Evaluate the Efficacy of Bevacizumab Plus Irinotecan in Recurrent Gliomas
• Treatment Strategy for Low-grade Gliomas
• Sorafenib in Newly Diagnosed High Grade Glioma
• Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma
• Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Anaplastic Astrocytoma
• Everolimus in Treating Patients With Recurrent Low-Grade Glioma
• Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma
• Everolimus in Treating Patients With Recurrent Low-Grade Glioma
• Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1)
• SCH 52365 Phase II Clinical Study: A Study on the Efficacy and Safety of Monotherapy With SCH 52365 in Patients With First Relapsed Anaplastic Astrocytoma (Study P03745)
• Everolimus (RAD001) for Children With Chemotherapy-Refractory Progressive or Recurrent Low-Grade Gliomas
• Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma
• Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant Gliomas
• Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma
• A Phase I Trial of Nanoliposomal CPT-11 (NL CPT-11) in Patients With Recurrent High-Grade Gliomas
• Temodal (Temozolomide) Post Marketing Surveillance Protocol (Study P05557AM2)
• Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide
• Temozolomide All-Case-Registered Surveillance (Designated Drug Use Investigation)(Study P05062)
• A Study of 131I-TM601 in Adults With Recurrent Malignant Glioma
• Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy
• Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors
• Aflibercept, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme, Gliosarcoma, or Other Malignant Glioma
• Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor
• PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 & 4 Malignant Gliomas
• Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas
• A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma
• Safety and Dose-Finding Study of TM-601 in Adults With Recurrent Malignant Glioma
• Phase 2a Study of AdV-tk With Standard Radiation Therapy for Malignant Glioma (BrTK02)
• Efficacy of Protracted Temozolomide in Patients With Progressive High Grade Glioma
• Sunitinib in Treating Patients With Recurrent Malignant Gliomas
• Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer
• Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma
• Radiotherapy for Malignant Astrocytomas in the Elderly
• Use of EF5 to Measure the Oxygen Level in Tumor Cells of Patients Undergoing Surgery or Biopsy for Newly Diagnosed Supratentorial Malignant Glioma
• Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex
• Phase IIa Safety and Light Dose-escalation Study in Patients With Primary or Recurrent/High-grade Glioma Using the Litx™ System to Confirm the Zone of Tumor Destruction During the Intraoperative Treatment of Glioma
• The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma Who Have Failed the Conventional 5-day (5/28) Treatment (P04601)
• A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma
• Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma
• Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma
• Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma
• Phase II Study of Irinotecan HCI for Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and Oligodendrogliomas
• Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644)
• AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
• Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma
• Treatment of Newly Diagnosed Brain Tumors With Chemotherapy and Radiation Using Cells Modified for Chemoprotection and an Experimental Drug to Decrease the Tumor Cell Resistance to Chemotherapy
• Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas
• Prolonged Daily Temozolomide for Low-Grade Glioma
• Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma
• 131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma
• Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma
• Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain Tumors
• Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas
• Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors
• Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors
• Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma
• Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment
• IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant Glioma
• FR901228 in Treating Patients With Recurrent High-Grade Gliomas
• A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant Gliomas
• Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors
• Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem Glioma
• Imaging Study of the Distribution of IL13-PE38QQR Infused Before and After Surgery in Adult Patients With Recurrent Malignant Glioma
• Cilengitide in Treating Children With Refractory Primary Brain Tumors
• Phase 2 Trial Using Talampanel in Patients With Recurrent High Grade Gliomas
• FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia
• Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors
• Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
• A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas
• Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma
• Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas
• Pre-operative IL13-PE38QQR in Patients With Recurrent or Progressive Malignant Glioma
• Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
• Chemotherapy and Radiation Therapy After Surgery in Treating Children With Newly Diagnosed Astrocytoma, Glioblastoma Multiforme, Gliosarcoma, or Diffuse Intrinsic Pontine Glioma
• Safety and Effectiveness Study of G207, a Tumor-Killing Virus, in Patients With Recurrent Brain Cancer
• Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors
• Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma
• Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma Patients
• Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas
• Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma
• Bortezomib in Treating Patients With Recurrent Glioma
• SU5416 in Treating Patients With Recurrent Astrocytoma or Mixed Glioma That Has Not Responded to Radiation Therapy
• Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms
• Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas
• Irinotecan in Treating Children With Refractory Solid Tumors
• IL-4(38-37)-PE38KDEL Immunotoxin in Treating Patients With Recurrent Malignant Astrocytoma
• Leflunomide in Treating Patients With Anaplastic Astrocytoma in First Relapse
• Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Anaplastic Astrocytoma
• Antineoplaston Therapy in Treating Adult Patients With Anaplastic Astrocytoma
• Antineoplaston Therapy in Treating Patients With Low-Grade Astrocytoma
• Antineoplaston Therapy in Treating Patients With Anaplastic Astrocytoma
• Antineoplaston Therapy in Treating Children With Low-Grade Astrocytoma
• Combination Chemotherapy in Treating Children With Progressive Brain Tumors
• Combination Chemotherapy for Patients With Brain Cancer
• Combination Chemotherapy in Treating Children With Astrocytomas and Primitive Neuroectodermal Tumors